GSK lawyer: CMA paroxetine decision was “overreach”
GlaxoSmithKline building, London (Credit: Ian Wilson - Flickr)
The UK’s antitrust watchdog was wrong to paint patent settlements between GlaxoSmithKline and two generic drugmakers as an illegal pay-for-delay scheme, counsel to the pharmaceutical company told the Competition Appeal Tribunal today.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now